Payment overview · 2025
General Payments
$330.05
14 reported records · 5 companies
Healthcare provider profile · identity verified
Murray L. Scheinman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHICAGO, IL · NPI 1467461921
Verified facts
What the public records show
CMS Open Payments records show Murray L. Scheinman, MD received $330.05 in general payments during 2025 across 14 reported records.
PFIZER INC. accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Paxlovid, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $92.23 | 27.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.13 | 24.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $75.45 | 22.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.64 | 17.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.60 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $330.05 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $81.13 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $81.13 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.64 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.53 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.53 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $50.68 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 135 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 21 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
207 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
135 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 370 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 264 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 210 | 31 |
| Jardiance | Empagliflozin | 207 | 17 |
| Omeprazole | Omeprazole | 165 | 36 |
| Metformin Hcl | Metformin Hcl | 154 | 27 |
| Furosemide | Furosemide | 145 | 33 |
| Losartan Potassium | Losartan Potassium | 139 | 26 |
| Eliquis | Apixaban | 135 | 16 |
| Gabapentin | Gabapentin | 128 | 23 |
| Simvastatin | Simvastatin | 126 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 19 |
| Meloxicam | Meloxicam | 106 | 23 |
| Tramadol Hcl | Tramadol Hcl | 104 | 23 |
| Trazodone Hcl | Trazodone Hcl | 94 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 22 |
| Potassium Chloride | Potassium Chloride | 76 | 14 |
| Carvedilol | Carvedilol | 72 | 13 |
| Mirtazapine | Mirtazapine | 72 | 16 |
| Lisinopril | Lisinopril | 71 | 19 |
| Famotidine | Famotidine | 65 | 13 |
| Ezetimibe | Ezetimibe | 63 | 13 |
| Azithromycin | Azithromycin | 62 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Ozempic | Semaglutide | 48 | suppressed |
| Allopurinol | Allopurinol | 47 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 17 |
| Lorazepam | Lorazepam | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Alprazolam | Alprazolam | 41 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 22 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Prednisone | Prednisone | 27 | 14 |
| Temazepam | Temazepam | 27 | suppressed |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | suppressed |
| Anastrozole | Anastrozole | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Risperidone Odt | Risperidone | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 19 |
| Lacosamide | Lacosamide | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Admelog | Insulin Lispro | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Tresiba | Insulin Degludec | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $330.05 · 14 records | PFIZER INC. | ABRYSVO, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, Rybelsus, The Cologuard Plus Collection Kit, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error